FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
Kathleen Jones
Advertisement
Kathleen Jones, PhD, is acting division deputy director, DMPQ, OCBQ, and CBER, at FDA.
Articles by Kathleen Jones
Advertisement
Latest Updated Articles
Advertisement
Advertisement